Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals shows a slight decrease today, losing -€0.100 (-0.570%) compared to yesterday.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -0.570% | -4.918% | -2.793% | -25.000% | -26.891% | -1.136% | -36.473% |
| Indivior plc | - | 1.370% | 15.625% | 171.560% | 152.991% | 42.308% | 414.335% |
| Viatris Inc. | -0.220% | 5.707% | 7.562% | -17.610% | -16.396% | -6.304% | -30.573% |
| Repligen Corp. | -0.790% | -2.788% | 4.952% | -6.894% | -1.572% | -16.404% | -9.016% |
Comments
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat